Tom Valuck Presents Strengths and Weaknesses of the Oncology Care Model

November 2019

Tom Valuck, MD, JD
Tom Valuck, MD, JD

In October, Journal of Clinical Pathways (JCP) editorial board member and Discern Health Partner Tom Valuck joined colleagues from the Community Oncology Alliance and the University of Chicago for the JCP Oncology Clinical Pathways Congress panel, “The Oncology Care Model: Current Opinions and Future Perspectives.”

During the panel, participants summarized the strengths and weaknesses of the current Oncology Care Model (OCM), one of the most advanced efforts yet to shift the delivery of health care from a fee-for-service model to a fee-for-value model. The panelists also discussed the importance of gaining a better understanding of the OCM through lessons learned, from both community and academic settings, and understanding the challenges to implementation in order to inform the creation of the next version of the OCM. In addition, they theorized how the next version of the OCM may be designed and what role it will play in future health care systems.

Discern created a Congress summary, which includes an overview of key themes and a session highlight from the presentation “Biosimilars and Oncology Clinical Pathways: Perfect Together.” Download the summary here.

For more information, please contact Gracelena Ignacio at gignacio@discernhealth.com.

Discern expands Health Economics and Outcomes Research (HEOR) Capabilities For Life Sciences clients

Health economics and outcomes research (HEOR) has long been important for health care market access outside the U.S., but it is increasingly being utilized in the U.S. as part of the movement from vol...
Learn More

About

About

Capabilities

Capabilities

Contact

Contact Us

Insights

Insights

Guy D’Andrea Speaks About Innovative Payment Models

Click here to view the VIDEO